Universal Ibogaine Inc. is an expanding Canadian-holding company with an average volume of $139K+ in the last 3 months. The average volume of the company in the last 10 days is $81.88K with $190.74M share outstanding. The stock price when the market opened was $0.045.
"We are happy to have access to Blue Digital's distribution channels, as their range across borders will broaden awareness of our business to new audiences," said Nick Karos, UI's Chief Executive Officer. Because addiction knows no bounds, the remedy we seek must be global in scope." As Blue Digital Media professional radar.
$IBO is one of the elite stocks in the market today and is racing ahead with full speed, the stock’s financial figures are pretty neat and is expected achieve great heights in the days to come, shares are trading at $0.05 with no losses as such
Universal Ibogaine Co-Founder Dr Alberto Sola has administered over 3700 ibogaine detox treatments, more than any other doctor in the world.
Universal Ibogaine Inc. is an expanding Canadian-holding company with an average volume of $172K+ in the last 3 months. The average volume of the company in the last 10 days is $97K with $190.16M share outstanding. The stock price when the market opened was $0.05.
$IBO is gliding swiftly on the TSX-V Index, the shares are trading currently at $0.05 which might get doubled in the upcoming days or week maximum.
Dr. Sola, a co-founder of Universal Ibogaine and a member of its Board of Directors, has effectively administered over 3,700 ibogaine treatments, more than any other doctor in the world, at an independent clinic in Cancun, Mexico, where he is a partner.
"H.C. Wainwright is a leader in the field and may be a significant strategic partner in our ongoing corporate finance roadmap," said Nick Karos, CEO of Universal Ibogaine. Another crucial step in raising awareness of our brand and service is the chance to share our story with this audience.
"The significance of this occasion cannot be emphasized," said CEO Nick Karos. This is the first gathering of academic researchers, real-world technicians, and government policymakers of its sort. This event will raise awareness of ibogaine's great potential at the highest levels."
"We are happy to have access to Blue Digital's distribution channels, as their range across borders will broaden awareness of our business to new audiences," said Nick Karos, UI's Chief Executive Officer. Because addiction knows no bounds, the remedy we seek must be global in scope." As Blue Digital Media professional radar.
Hemostemix Inc. announced that in accordance with its stock option plan, it has granted on February 28, 2022, subject to regulatory approval, a total of 1,494,269 stock options to purchase common shares of Hemostemix to directors, officers, employees and consultants of Hemostemix
Julie Dumouchel has been named Director of Clinical Trials at UI, which is a significant strategic move. Julie Dumouchel has 25 years of experience in the pharmaceutical sector, where she has worked in a variety of clinical research jobs and has a thorough grasp of the drug development process.
Universal Ibogaine Inc. holds a significant position over the OTC market with its greater difference between the lower and higher ranges of trading, which is $0.0258-$0.1143 in the last 52 weeks.
Universal Ibogaine Inc. is an expanding Canadian-holding company with an average volume of 138 K+ in the last 50 days . The average volume of the company in the last 10 days is $88.98K with $190.74M share outstanding. The stock price when the market opened was $0.05
Universal Ibogaine Inc. is a life science company listed on OTC with the ticker symbol $IBOGF. In the last 52 weeks the range of the lower and upper price is $0.0258-$0.1143.
The Company newly reported that its common shares, coined as "JC4", have been accepted for trade on the Frankfurt Stock Exchange, or Boerse Frankfurt. In Canada, UI will keep trading on the TSX Venture Exchange under the ticker IBO and on the OTCQB under the stock symbol IBOGF.
Our mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery. While seeking to move Ibogaine through Clinical Trials in Canada, we are building a network of holistic recovery clinics and a state of the art treatment program centred around new treatment modalities.
Neuropathic pain syndromes can be treated with NCP-01 and its autologous stem cell technology, which can treat disorders of the central and peripheral nervous systems. Spinal cord injury, chronic brainstem injury, traumatic brain injury, and peripheral nerve injury are all examples of traumatic injuries and many more